drugset / Trial / NCT06457477
Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective study to evaluate the safety and efficacy of Sintilimab (PD-1 antibody) in sequential combination with Peg-IFNα-2b in NA-supressed CHB patients who had previously received Peg-IFNα therapy.
Timeline
- Start
- 2024-06-15
- Primary completion
- 2025-12-15
- Completion
- 2025-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peg-IFNα-2b | Protein / enzyme biologic | 180 ug | — |
| Subject | Sintilimab | Monoclonal antibody | 100 mg | — |
| Background | ETV | Unknown | — | — |
| Background | TAF | Unknown | — | — |
| Background | TDF | Unknown | — | — |